-
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
11 Dec 2025 12:00 GMT
… and PK
No serious treatment-emergent adverse events were … medical oversight. About the CANYON-1 CRB-913 Phase 1b Clinical Trial … brain:plasma ratio than rimonabant (an extensively studied first … agonist). About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a …
-
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
10 Dec 2025 21:01 GMT
… brain:plasma ratio than rimonabant (an extensively studied first … inverse agonist for the treatment of obesity. Corbus is … timing for completion of trials and presentation of data, …
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com Dan …
-
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
12 Nov 2025 13:00 GMT
… inverse agonist drug candidate designed for the treatment of obesity. … than either monlunabant or rimonabant. CRB-913 has … timing for completion of trials and presentation of data …
daniel@lifesciadvisors.com
Corbus Pharmaceuticals Holdings, Inc.
Condensed …
-
Beyond weight loss: the gap in current drug development for obesity
07 Nov 2025 10:19 GMT
… of patients that initiate medical treatment (some form of glucagon … such as the peptide drugs semaglutide and tirzepatide … additional obstacles
Recent clinical trials using incretin-based therapies, … suicide rate observed with rimonabant or the increased cancer …
-
Novel Weight-Loss Drug Shows Promise in Obesity Treatment
23 Oct 2025 13:35 GMT
… the treatment of obesity, but first-generation drugs such as rimonabant … conducted a phase 2a trial in Canada to evaluate … was not conducted after treatment discontinuation. Additionally, the … other ties with other pharmaceutical companies.
This article was …
-
Skye Bio Obesity Drug Fails in Phase 2; Hopes Now Ride on Higher Doses and Combo Treatment
06 Oct 2025 22:09 GMT
… approval in 2006 for rimonabant, an oral small … potential future clinical trials,” Chief Medical Officer Puneet Arora … showed neuropsychiatric effects. Corbus Pharmaceuticals’ CRB-913 is also … discontinuing treatment. That could give the Skye drug a …
-
The Evolution of Obesity Drugs: Lessons from a Century of Failures and the GLP-1 Breakthrough
25 Sep 2025 14:25 GMT
… treatments, writing them off as “cosmetic.” As a result, pharmaceutical … to sibutramine, many drugs raised blood pressure, … risk.
Psychiatric complications: Rimonabant and stimulants produced depression, … as Wegovy.
Clinical trials showed average weight loss …
-
Diet pills and muscle-building supplements pose a threat for minors in Missouri
27 Aug 2025 12:32 GMT
… liver transplant.
Although doctors managed to save his … , rimonabant, cetilistat and other chemicals linked to detrimental medical consequences … drugs, meaning most can be sold without prior FDA … are turning to diet pills and muscle-building supplements …
-
Doctor Reveals 3 Ways to Know If Your Supplement Is Real or Fake
22 Aug 2025 13:42 GMT
… TikTok video, naturopathic doctor and health advocate Janine … phenolphthalein, phenytoin, bumetanide, and rimonabant. Results showed that “adulterated … -fortified foods.
RELATED: Doctor Says These 10 Supplements … it comes to the medication you're taking …
-
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
05 Aug 2025 12:00 GMT
… receptor inverse agonist drug designed for the treatment of obesity. … than either monlunabant or rimonabant. CRB-913 has … timing for completion of trials and presentation of data … tables to follow---
Corbus Pharmaceuticals Holdings, Inc.
Condensed Consolidated …